Specialty Pharmacy

Prescribing and dosing appropriate treatments for patients with sickle cell disease while managing episodes of acute pain are some of the integral roles of pharmacists.

Amlenetug could provide a treatment option for patients with multiple system atrophy, a progressive and rare condition that causes damage to the brain’s nerve cells.

A one-time infusion of etranacogene dezaparvovec-drlb led to sustained bleeding control and a reduction in factor IX prophylaxis in patients with hemophilia B.

Through frequent interactions, pharmacists can discuss patients' treatment satisfaction, adherence issues, or potential adverse events.

Supplements, such as Prevagen, as well as lifestyle and diet modifications can provide additional support to patients with Alzheimer disease.

The approval is based on positive clinical trial results that indicated deep and durable reductions in plexiform neurofibroma.

Thalassemia, a chronic blood condition that reduces hemoglobin levels, requires a hands-on approach from pharmacists in patient monitoring and diagnosis.

These findings can lay the foundation for the development of machine learning models in chronic kidney disease (CKD) and kidney failure.

Compared with other treatments for myasthenia gravis, nipocalimab demonstrated more significant improvements in disability scores, with tolerable safety.

The designation builds on previous regulatory action for ADI-001 and allows for expedited development of the treatment for systemic lupus erythematosus.

More accurate prognostic risk assessment could aid pharmacists in the management and counseling of patients with primary myelofibrosis.

Proteolysis-targeting chimeras hold enormous potential, but also present significant challenges to drug developers.

There were no substantial differences for the mindfulness with substance use or anxiety outcomes compared with the recovery control group.

Higher p16 expression in patients with sickle cell disease led to heightened risk of age-related complications.

NK is a degenerative corneal disease resulting from diminished corneal innervation.

Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).

Some risk factors for chronic kidney disease (CKD) in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) were renal impairment, delayed diagnosis, and hypertension.

Fitusiran is part of a generation of novel RNA interference therapies and is designed for subcutaneous administration for the prophylactic treatment of hemophilia A or B.

These results provide a pediatric lens into the potential risk of thromboembolic events in patients with dermatomyositis.

The model also predicted prevalent cases of decompensated cirrhosis would more than triple, incident liver cancer cases would nearly double, and transplant almost quadruple.

The regenerative medicine advanced therapy designation expedites the development and review of regenerative medications that have the potential to address unmet needs for serious or life-threatening diseases.

The approval includes indications for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.

Meloxicam and rizatriptan reduces migraine pain and help patients return to normal functioning with efficacy through 24 to 48 hours after a single dose for some patients.

Apitegromab is a muscle-targeted therapy for improvement of motor function in individuals with spinal muscular atrophy.

Through similar targeting of the RdRp enzyme, these treatments could offer groundbreaking new options for patients with COVID-19 if proven effective in real-world trials.

The authors note that transferrin saturation levels may be a modifiable risk factor of chronic kidney disease (CKD) progression and all-cause mortality.

Gender-affirming care and inclusive practices are essential for health equity.

The new indication for semaglutide adds to the long list of conditions that the GLP-1 receptor agonist has been approved for, and provides a new option for high-risk patients with these chronic conditions.

Axatilimab-csfr is a colony-stimulating factor-1 receptor (CSFR1) blocking monoclonal antibody indicated for cGVHD after 2 or more lines of prior therapy in adults and pediatric patients that weigh at least 40 kg.

Patients with myelofibrosis have a higher likelihood of having a cardiovascular risk factor when compared with essential thrombocythemia or polycythemia vera.